Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis/Orion triple-combo Parkinson’s submission

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Novartis and Orion Pharma submit NDA for first triple-combination Parkinson's disease therapy, the firms announce Aug. 26. The combination adds entacapone (Orion's Comtan) to the standard regimen for Parkinson's: levodopa and carbidopa. Entacapone, which is approved for patients with idiopathic Parkinson's disease who experience signs and symptoms of end-of-dose "wearing off," reduces the breakdown of levodopa, allowing it to remain therapeutically available for longer periods between doses. A triple-combination product would provide more convenient dosing, the firms sa

You may also be interested in...

Novartis/Orion Stalevo for Parkinson’s

Novartis/Orion's idiopathic Parkinson's disease therapy Stalevo (carbidopa, levodopa and entacapone) clears FDA June 11. The combination product adds entacapone (Novartis/Orion's Comtan) to the standard Parkinson's regimen of levodopa/carbidopa. Labeling says Stalevo can be used as a substitute for taking levodopa/carbidopa and Comtan separately. The firms have highlighted more convenient dosing as an advantage of the combo product (1Pharmaceutical Approvals Monthly Sept. 1, 2002, p. 59

Neuraxpharm Allies With Panaxia On Cannabis Portfolio

CNS specialist Neuraxpharm has struck a deal with Israel’s Panaxia to market medical cannabis products in Europe, starting in Germany.

AAM Urges Trump Not To Destabilize Supply Chain

The AAM has warned the Trump administration that ‘Buy American’ requirements on medicines could limit patient access to affordable medicines and increase the risk of drug shortages during the coronavirus pandemic.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts